Evidence vs. Access: Can Twenty‐First‐Century Drug Regulation Refine the Tradeoffs?
暂无分享，去创建一个
As the pharmaceutical industry productivity crisis worsens, there are calls for regulatory changes to support innovation. At the same time, prescribers and payers desire more information about drugs at the time they are released to the market. Will new regulatory schemes be able to accommodate these disparate needs?
[1] J. Arrowsmith. Trial watch: Phase III and submission failures: 2007–2010 , 2011, Nature Reviews Drug Discovery.
[2] Mark S Levenson,et al. Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthma. , 2011, The New England journal of medicine.
[3] H. Eichler,et al. Adaptive Licensing: Taking the Next Step in the Evolution of Drug Approval , 2012, Clinical pharmacology and therapeutics.